Everything below concerns research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Their size: Varies from a handful of researches to several hundred. The division of labor: Work divided among those working in the laboratory and all other professions involved in the course of the research, ranging from approving committees to designers, technicians, and researchers. The coordination mechanisms: Which includes the formalization of objectives and tasks; the standardization of procedures (protocols, project management, quality management, knowledge management), the validation of publications and cross-cutting activities (number and type of seminars). There are three main factors that contribute to the organizational form of a laboratory :
Organic compounds introduced on Earth by interstellar dust particles can help to form complex molecules, thanks to their peculiar surface-catalytic activities. The RNA component uracil and related molecules, including xanthine, in the Murchison meteorite were likely formed extraterrestrially, as suggested by studies of 12C/13C isotopic ratios. NASA studies of meteorites suggest that all four DNA nucleobases (adenine, guanine and related organic molecules) have been formed in outer space. The cosmic dust permeating the universe contains complex organics ("amorphous organic solids with a mixed aromatic–aliphatic structure") that could be created rapidly by stars. Glycolaldehyde, a sugar molecule and RNA precursor, has been detected in regions of space including around protostars and on meteorites.
== See also == Golden Crescent Golden Triangle History of Jardine, Matheson & Co. Illegal drug trade in Colombia Mexican drug war Nabidh Opium dollar Opium replacement Protocol for Limiting and Regulating the Cultivation of the Poppy Plant, the Production of, International and Wholesale Trade in, and Use of Opium Psychoactive drug Society for the Suppression of the Opium Trade Morphine Heroin
== History == Tablets designed to dissolve on the buccal (cheek) mucous membrane were a precursor to the ODT. This dosage form was intended for drugs that yield low bioavailability through the digestive tract but are inconvenient to administer parenterally, such as steroids and narcotic analgesics. Absorption through the cheek allows the drug to bypass the digestive tract for rapid systemic distribution. Not all ODTs have buccal absorption and many have similar absorption and bioavailability to standard oral dosage forms with the primary route remaining GI absorption. However, a fast disintegration time and a small tablet weight can enhance absorption in the buccal area. The first ODTs disintegrated through effervescence rather than dissolution, and were designed to make taking vitamins more pleasant for children. This method was adapted to pharmaceutical use with the invention of microparticles containing a drug, which would be released upon effervescence of the tablet and swallowed by the patient. Dissolution became more effective than effervescence through improved manufacturing processes and ingredients (such as the addition of mannitol to increase binding and decrease dissolution time). Catalent Pharma Solutions (formerly Scherer DDS) in the U.K., Cima Labs and Fuisz Technologies (whose founder Richard Fuisz went on to pioneer orally soluble films, a separate but related dosage form) in the U.S. and Takeda Pharmaceutical Company in Japan led the development of ODTs. The first ODT form of a drug to get approval from the U.S.
The true percentage utilization (usually shown with a percent symbol). The percentage utilization relative to a readily utilizable protein source, often egg (usually shown as unitless). The two values will be similar but not identical. The BV of a food varies greatly, and depends on a wide variety of factors. In particular the BV of a food varies depending on its preparation and the recent diet of the organism. This makes reliable determination of BV difficult and of limited use — fasting prior to testing is universally required in order to ascertain reliable figures. BV is commonly used in nutrition science in many mammalian organisms, and is a relevant measure in humans. It is a popular guideline in bodybuilding in protein choice.
Sources: en.wikipedia.org
where w0 is total enthalpy. For a calorically perfect gas such as an ideal gas, the enthalpy is directly proportional to the temperature, and this leads to the concept of the total (or stagnation) temperature. When shock waves are present, in a reference frame in which the shock is stationary and the flow is steady, many of the parameters in the Bernoulli equation suffer abrupt changes in passing through the shock. The Bernoulli parameter remains unaffected. An exception to this rule is radiative shocks, which violate the assumptions leading to the Bernoulli equation, namely the lack of additional sinks or sources of energy.
Especially the case of the community of Sarayaku has become well known among the Kichwa of the lowlands, who after years of struggle were able to successfully resist expropriation and exploitation of the rain forest for petroleum recovery.
2 CH3OH + O2 → 2 CH2O + 2 H2O The silver-based catalyst usually operates at a higher temperature, about 650 °C. Two chemical reactions on it simultaneously produce formaldehyde: that shown above and the dehydrogenation reaction
The following day, it was reported that Paetongtarn informed the Move Forward Party leaders that Pheu Thai Party needed to bring the Palang Pracharath Party, led by General Prawit Wongsuwan, into the coalition government. This led to the Move Forward Party deciding, six days later, not to support Pheu Thai's prime ministerial candidate. Following weeks of debate, Srettha was elected prime minister by the parliament of Thailand. On 13 September 2023, during the first meeting of the 63rd Thai Cabinet, Prime Minister Srettha Thavisin ordered the establishment of the National Soft Power Strategy Committee and appointed Paetongtarn as the Deputy Chairperson. Later, on 3 October, Srettha appointed her to two additional positions: Chairperson of the National Soft Power Development Committee and a member of the Committee for the Organization of Celebrations for King Vajiralongkorn's 72nd Birthday Anniversary on 28 July 2024. Subsequently, on 7 October, Srettha appointed her as the Deputy Chairperson of the National Health System Development Committee. On 27 October 2023, Paetongtarn was elected by the PTP's core members during a general assembly held at the party's head office to become the party's new leader, receiving 289 votes with one abstention.
== Morphology == Fully submerged aquatic plants have little need for stiff or woody tissue as they are able to maintain their position in the water using buoyancy typically from gas filled lacunaa or turgid aerenchyma cells. When removed from the water, such plants are typically limp and lose turgor rapidly. Those living in rivers do, however, need sufficient structural xylem to avoid being damaged by fast flowing water and they also need strong mechanisms of attachment to avoid being uprooted by river flow. Many fully submerged plants have finely dissected leaves, probably to reduce drag in rivers and to provide a much increased surface area for interchange of minerals and gasses. Some species of plants such as Ranunculus aquatilis have two different leaf forms which changes depending on growing conditions. Leaves are usually fully submerged and form a branch-like pattern that resembles a fan. They may also possess floating leaves that contain 3 to 5 lobes which are flat. Some still-water plants can alter their position in the water column at different seasons. One notable example is water soldier, which rests as a rootless rosette on the bottom of the water body but slowly floats to the surface in late spring so that its inflorescence can emerge into the air. While it is ascending through the water column it produces roots and vegetative daughter plants by means of rhizomes. When flowering is complete, the plant descends through the water column and the roots atrophy.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.